Evercore ISI Raises Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $260.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target lifted by Evercore ISI from $220.00 to $260.00 in a research note published on Tuesday,Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the stock. Oppenheimer lowered their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Stifel Nicolaus increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research note on Friday, November 15th. UBS Group started coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective on the stock. The Goldman Sachs Group increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, Ascendis Pharma A/S has an average rating of “Moderate Buy” and an average price target of $197.36.

Ascendis Pharma A/S Stock Up 9.1 %

Shares of ASND opened at $157.17 on Tuesday. The company has a 50-day simple moving average of $133.20 and a 200-day simple moving average of $132.57. The company has a market capitalization of $9.54 billion, a PE ratio of -19.45 and a beta of 0.64. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. On average, research analysts anticipate that Ascendis Pharma A/S will post -7.12 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Woodline Partners LP lifted its holdings in shares of Ascendis Pharma A/S by 35.2% during the 4th quarter. Woodline Partners LP now owns 317,642 shares of the biotechnology company’s stock worth $43,730,000 after acquiring an additional 82,624 shares during the period. Zimmer Partners LP lifted its holdings in shares of Ascendis Pharma A/S by 24.2% during the 4th quarter. Zimmer Partners LP now owns 96,900 shares of the biotechnology company’s stock worth $13,340,000 after acquiring an additional 18,900 shares during the period. Vestal Point Capital LP lifted its holdings in shares of Ascendis Pharma A/S by 108.0% during the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company’s stock worth $71,588,000 after acquiring an additional 270,000 shares during the period. Soleus Capital Management L.P. purchased a new position in Ascendis Pharma A/S in the fourth quarter valued at approximately $19,824,000. Finally, Tema Etfs LLC purchased a new position in Ascendis Pharma A/S in the fourth quarter valued at approximately $2,621,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.